Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070.SR) — Cash flow
Operating, investing, and financing cash flow for Saudi Pharmaceutical Industries and Medical Appliances Corporation — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | 184↑476.1% | 32↑455.6% | -9↑93.8% | -146↓563.5% | 32 | |
| Depreciation & Amortization | 97↑14.3% | 85↑8.2% | 79↓13.0% | 90↑2.5% | 88 | |
| Deferred Income Tax | -0.89 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes in Working Capital | -51↑86.6% | -380↓40.2% | -271↓11715.1% | 2↓83.1% | 14 | |
| Accounts Receivable | -23↑93.2% | -341↓111.1% | -162↓193.7% | 173↑1226.3% | 13 | |
| Inventory | 26↑152.0% | -50↑65.3% | -143↓182.8% | 173↑858.1% | 18 | |
| Accounts Payable | -59↓151.0% | 116↑12.4% | 104↑278.6% | -58↓306.3% | -14 | |
| Other Working Capital | 6↑105.6% | -106↓50.9% | -70↑75.5% | -285↓9418.4% | -3 | |
| Other Non-Cash Items | 43↑162.8% | -68↓127.3% | 249↑453.4% | -71↓51.0% | -47 | |
| Net Cash from Operating Activities | 272↑182.3% | -331↓793.4% | 48↑138.4% | -124↓243.2% | 87 | |
| Operating Cash Flow | 272↑182.3% | -331↓793.4% | 48↑138.4% | -124↓243.2% | 87 | |
| Investing Activities | ||||||
| Investment in Property, Plant & Equipment | -100↓48.6% | -67↑39.9% | -111↓31.6% | -85↓0.9% | -84 | |
| Capital Expenditure | -89↓33.0% | -67↑42.9% | -117↓38.7% | -85↓0.9% | -84 | |
| Acquisitions | 40 | 0.00↓100.0% | 4↑0.2% | 4↑280.3% | -2 | |
| Purchases of Investments | -150 | 0.00↑100.0% | -71↓56.7% | -45↑69.0% | -145 | |
| Sales & Maturities of Investments | 125 | 0.00 | 0.00↓100.0% | 571↑67.2% | 341 | |
| Other Investing Activities | 0.00↑100.0% | -26↓534.6% | 6↓81.6% | 33↑3.1% | 32 | |
| Net Cash from Investing Activities | -85↑8.6% | -93↑45.8% | -172↓135.9% | 478↑238.0% | 141 | |
| Financing Activities | ||||||
| Net Debt Issuance | -102↓125.4% | 400↑811.2% | 44↑121.4% | -206↓234.1% | -62 | |
| Long-Term Net Debt Issuance | 0.00↓100.0% | 400↑811.2% | 44↑487.7% | 7↓48.3% | 14 | |
| Short-Term Net Debt Issuance | -102 | 0.00 | 0.00↑100.0% | -213↓180.3% | -76 | |
| Net Stock Issuance | 0.00↑100.0% | -12↓49.2% | -8 | 0.00 | 0.00 | |
| Net Common Stock Issuance | 0.00↑100.0% | -12↓49.2% | -8 | 0.00 | 0.00 | |
| Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Share Buybacks | 0.00↑100.0% | -12↓49.2% | -8 | 0.00 | 0.00 | |
| Net Preferred Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | 0.00↑100.0% | -3↓502.6% | -0.46↑99.3% | -71↑40.1% | -118 | |
| Common Dividends Paid | 0.00↑100.0% | -3↓502.6% | -0.46↑99.3% | -71↑40.1% | -118 | |
| Preferred Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | -2↑48.9% | -5↑93.2% | -68↓4.6% | -65↓5.7% | -61 | |
| Net Cash from Financing Activities | -104↓127.3% | 381↑1280.7% | -32↑89.6% | -311↓29.0% | -241 | |
| Cash Reconciliation | ||||||
| Effect of Foreign Exchange | -2↓185.4% | 2↑112.1% | -16↑56.9% | -37↓548.9% | 8 | |
| Net Change in Cash | 82↑299.7% | -41↑76.2% | -172↓150.5% | 341↑4.9% | 325 | |
| Cash at Beginning of Period | 122↓25.1% | 163↓51.4% | 335↑1.7% | 330↓1.3% | 334 | |
| Cash at End of Period | 204↑66.9% | 122↓25.1% | 163↓75.7% | 671↑1.7% | 659 | |
| Income Taxes Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Paid | 0.00↓100.0% | 107 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 183↑146.0% | -398↓471.7% | -70↑66.7% | -209↓7468.5% | 3 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.